Biotech Company** | Product | Pharma Partner | Type Arrangement/Geographic Area/ |
(Country) | (Country) | Details (Date) | |
AltaRex Corp. | Ovarex therapeutic | Medac GmbH | AltaRex reacquired marketing rights in |
(Canada) | vaccine for delaying | (Germany) | Western Europe from Medac; AltaRex |
time to relapse in | decided to terminate all European clinical | ||
ovarian cancer patients | trials for the present because it is conduct- | ||
and for improving | ing 2 parallel trials in North America (1/98) | ||
survival in these patients | |||
(based on anti-idiotype | |||
induction therapy; | |||
2 Phase II/III North | |||
American clinical trials | |||
ongoing) | |||
Anesta Corp. | Product line of oral | Grupo Ferrer (Spain) | Ferrer has exclusive right to market, sell |
transmucosal fentanyl | and distribute products in Spain and | ||
products, including | Portugal (1/98) | ||
Actiq (for treating | |||
breakthrough pain in | |||
cancer patients) | |||
Athena Neurosciences | Wyeth-Ayerst's prod- | Wyeth-Ayerst Labor- | Elan acquired exclusive product distribution |
Inc. (wholly owned | uct Mysoline (primi- | atories (division of | rights and trademark in U.S. and Canada; |
subsidiary of Elan | done; anticonvulsant | American Home | agreement subject to clearance by Federal |
Corp. plc; Ireland) | for treating epilepsy | Products Corp.; | Trade Commission (2/98) |
and seizure disorders) | NYSE:AHP) | ||
Bio-Technology | GrowJect Injectable | JCR Pharmaceuticals | JCR is Bio-Technology General's Japanese |
General Corp. | (recombinant human | Co. Ltd. and Sumitomo | licensee for this product; JCR will supply |
growth hormone) | Pharmaceuticals Co. | Sumitomo with product, which Sumitomo | |
Ltd. (both Japan) | will distribute in Japan beginning in 1/99 | ||
(following the termination of its distribu- | |||
tion agreement for Pharmacia & Upjohn | |||
Inc.'s Genotropin at the end of 1998) (1/98) | |||
Biomatrix Inc. | Synvisc (elasto- | Novartis Pharma AG | Novartis gets exclusive marketing and dis- |
viscous hylan bio- | (Switzerland) | tribution rights in Mexico, Central America, | |
polymer for treating | South America and the Caribbean; Bio- | ||
osteoarthritis of knee; | matrix gets $3.5M in fees; Novartis respon- | ||
FDA approved 8/97) | sible for marketing approvals in its territor- | ||
ies; Novartis also will conduct post-market- | |||
ing clinical trials in Mexico, Argentina and | |||
Brazil (3/98) | |||
BioTime Inc. | Hextend (synthetic blood | Nihon Pharmaceutical | Letter of intent to negotiate licensing agree- |
plasma volume expand- | Co. Ltd. (Japan) | ment for Nihon to manufacture and market | |
er) to replace blood lost | product in Japan (1/98) | ||
in surgery or trauma | |||
(NDA submitted 12/97) | |||
Centocor Inc. | Retevase (reteplase; | Roche Healthcare Ltd. | As part of its purchase of Corange Ltd. (the |
recombinant plasmino- | (affiliate of Roche | parent company of Boehringer Mannheim | |
gen activator) for | Holding Ltd.; | GmbH, the manufacturer and marketer of | |
treating acute myo- | Switzerland) | Retevase), the Federal Trade Commission | |
cardial infarction | required Roche to divest Retevase; Cento- | ||
(FDA approved 10/96) | cor paid $335M cash for the U.S. and | ||
Canadian rights to the product (including | |||
intellectual property and various marketing | |||
assets) (definitive agreement 2/98; finalized | |||
3/98) | |||
Cephalon Inc. | Aguettant's Apokinon | Laboratoire Aguettant | Cephalon's U.K. subsidiary has 10-year |
(apomorphine HCl) for | SA (France) | agreement to market product in France; | |
treating Parkinson's | further details ND (1/98) | ||
disease | |||
Genentech Inc. | Recombinant human | Sumitomo Pharma- | Sumitomo gets exclusive rights to develop, |
growth hormone (hGH) | ceuticals Co. Ltd. | import and distribute both products in | |
products Nutropin AQ | (Japan) | Japan; Genentech got large up-front payment | |
(FDA-approved) and | and also gets milestones; Genentech and | ||
ProLease hGH (sustained- | Alkermes will manufacture products for | ||
release formulation of | sale to Sumitomo (1/98) | ||
hGH, employs Alkermes | |||
Inc.'s drug delivery | |||
technology; currently | |||
in U.S. Phase III trials | |||
for growth hormone- | |||
deficient children) | |||
Immunomedics Inc. | CEA-Scan (radiolabeled | Bergen Brunswick | Bergen Brunswick will distribute product |
monoclonal antibody- | Specialty Co. (wholly | in U.S. after the Mallinckrodt agreement | |
based in vivo diagnostic | owned subsidiary of | terminates in 4/98 (see below) (3/98) | |
imaging agent for colo- | Bergen Brunswick | ||
rectal cancer) | Corp.; NYSE:BBC) | ||
CEA-Scan (radiolabeled | Mallinckrodt Group | Termination of marketing and distribution | |
monoclonal antibody- | Inc. (NYSE:MKG) | agreements in Europe (from 3/95) and U.S. | |
based in vivo diagnostic | (from 4/96); Immunomedics said its deci- | ||
imaging agent for colo- | sion was strategic; Eli Lilly and Co. (which | ||
rectal cancer) | agreed in 12/97 to distribute Immuno- | ||
medics' infectious disease imaging agent | |||
LeukoScan in Europe) will handle distribu- | |||
tion of CEA-Scan, as well (2/98) | |||
Integra LifeSciences | Two products used in | Century Medical Inc. | Century Medical gets rights to distribute |
Corp. | surgical procedures to | (wholly owned sub- | products in Japan; further details ND (1/98) |
control bleeding (Heli- | sidiary of Itochu | ||
stat and Helitene, both | Corp.; Japan) | ||
made of absorbable | |||
collagen) | |||
Integra LifeSciences | Two neurosurgery prod- | Century Medical Inc. | This is 3rd agreement between companies; |
Corp. | ucts: dural regeneration | (wholly owned subsid- | Century Medical gets rights to distribute |
device (collagen-based | iary of Itochu Corp.; | products in Japan; Integra gets up-front fee | |
matrix) and peripheral | Japan) | of $1M in 1Q:98; Century will buy $4M of | |
nerve regeneration | Integra preferred stock (0.5M shares) in | ||
conduit (thin collagen | 2Q:98; Century Medical will fund all costs | ||
tube) | of product development and approval in | ||
Japan; 7-year distribution rights begin on | |||
day of product approval in Japan (3/98) | |||
Isis Pharmaceuticals | Antisense oligo- | Zeneca LifeScience | Five-year contract; Zeneca will manufacture |
Inc. | nucleotides | Molecules (division | antisense oligonucleotides for use in Isis' |
of Zeneca Group plc; | clinical trials and for sale to 3rd parties; | ||
NYSE:ZEN; U.K.) | financial terms ND (3/98) | ||
Matritech Inc. | NMP22 test kit for | Curtin Matheson Sci- | Curtin Matheson will distribute product in |
management of patients | entific/Fisher Health- | U.S. (3/98) | |
with bladder cancer | Care (division of | ||
(enzyme immunoassay | Fisher Scientific Inter- | ||
that measures cancer- | national Inc.) | ||
specific nuclear matrix | |||
protein antigens in urine; | |||
FDA-approved 7/96) | |||
Penederm Inc. | Alpharma's permethrin | Alpharma Inc. | Penederm will market product in U.S. under |
cream 5% (topical treat- | (NYSE:ALO) | its Acticin brand name; Alpharma will manu- | |
ment of scabies infection; | facture and supply product to Penederm; | ||
FDA approved 1/98) | Alpharma gets milestones and royalties (1/98) | ||
Ribi ImmunoChem | Melacine melanoma | Schering-Plough | Schering-Plough gets exclusive worldwide |
Research Inc. | vaccine (lysed, purified | Corp. (NYSE:SGP) | rights (except Canada) to distribute, market |
cells from 2 human | and sell product; Ribi gets $30M in signing | ||
melanoma cell lines | fees and milestones on gaining U.S. and Euro- | ||
combined with Detox | pean marketing approvals for Melacine as | ||
adjuvant) | monotherapy for Stage IV disease; additional | ||
milestones on gaining U.S. and European ap- | |||
provals for Melacine as either combination | |||
therapy with Intron A for Stage IV disease | |||
or as monotherapy for preventing recurrence | |||
of Stage II disease; Ribi also gets transfer pay- | |||
ments for supplies of Melacine and margins | |||
on sales (3/98) | |||
TheraTech Inc. | TheraTech's oral trans- | SmithKline Beecham | SmithKline gets worldwide marketing |
mucosal nicotine product | plc (NYSE:SBH; U.K.) | rights (except in South Korea); TheraTech | |
(for smoking control) | gets signing fees, R & D payments, mile- | ||
stones and royalties (2/98) | |||
Vion Pharmaceuticals | Vion's Melasyn technology | San Mar Laboratories | San Mar gets exclusive worldwide license to |
Inc. | (soluble form of melanin) | manufacture, market and sell products con- | |
for use in skin care prod- | taining Melasyn; Vion gets guaranteed annual | ||
ucts and cosmeceuticals | royalties over initial 3-year period (2/98) | ||
NOTES: | |||
# This chart does not include any marketing and/or distribution agreements that involve agricultural product development. The information in the chart covers the time period between 1/1/98 and 3/24/98. | |||
ND = Not disclosed, reported and/or available | |||
** Unless otherwise noted, the trading symbols for public biotechnology companies can be found by referring to the BioWorld Stock Report For Public Biotechnology Companies on pp. 13-14. |